Followers | 13 |
Posts | 1546 |
Boards Moderated | 0 |
Alias Born | 06/14/2018 |
Wednesday, June 01, 2022 6:24:40 PM
YOU SAID: "How do you know that 99% of publicly traded biotech isn't just a way to offload BP's cost for research?"
I KNOW that because I have a functioning brain and therefore I understand that when you generalize "99%" of anything into one group it is most likely not going to be accurate.
OK, How do you KNOW that what you said is TRUE?
PROVE to me and all on this board that 99% of public biotech companies are just being used to fund the research cost for big pharma at the expense of small investors.
That is what you are implying. How do you KNOW that? Back up to all of us and prove your words. Or are they just empty words with absolutely NOTHING of any meaning or importance to back them up?
They are just empty meaningless words solely for the sake of being negative.
YOU SAID: "Perhaps handsomely paid biotech executives are all in on the game of research for researches sake, paid for by naive retail where they never really had a chance."
That statement at least may be TRUE, in a small part, but the FOOLISH use of the word "ALL" in your statement again gets us back to empty meaningless words.
I will explain so that maybe you can understand logic and reason.
YES, there may be a SMALL percentage of biotech executives who are in it for "the game of research for researches sake" because they just want to do research or because they just want a paycheck or because they want to make a name for themselves or because they want to win the Nobel prize or for whatever reason ..., when they KNOW they have no chance of succeeding as you imply.
BUT to say "ALL" again is just asinine.
SO AGAIN, PROVE your empty words.
PROVE that NOT A SINGLE biotech executive is in it for a good cause, to try to save and cure patients.
PROVE that they are ALL in it just for the money.
AGAIN just negative nonsense for the sole purpose of being negative.
AGAIN just EMPTY MEANINGLESS WORDS just to spout something negative.
It is NOT that I have "some pretty low standards" for the company management, I just have REALISTIC standards because I understand they can only work with what they have to work with.
I am sure they all WISH the trial data was further along and was Much better, but again, in real life, they do not have a magic wand to wave to make it that way.
PLEASE tell me what YOU would have done differently with the trials that they have going on, that would have the share price so much higher than it is right now, which is based on what every other stock price is based on and that is what the market thinks it is currently worth.
PLEASE give us all your list of brilliant ideas that you would have executed differently and then tells us why you believe they would have resulted in a much higher stock price.
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM